OSPHENA Drug Patent Profile

« Back to Dashboard

When do Osphena patents expire, and when can generic versions of Osphena launch?

Osphena is a drug marketed by Duchesnay and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in OSPHENA is ospemifene. One supplier is listed for this compound. Additional details are available on the ospemifene profile page.

DrugPatentWatch^® Generic Entry Outlook for Osphena

Osphena was eligible for patent challenges on February 26, 2017.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for OSPHENA

US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OSPHENA

Paragraph IV (Patent) Challenges for OSPHENA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OSPHENA	Tablets	ospemifene	60 mg	203505	1	2020-12-29

US Patents and Regulatory Information for OSPHENA

OSPHENA is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013		RX	Yes	Yes
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013		RX	Yes	Yes			Y

International Patents for OSPHENA

When does loss-of-exclusivity occur for OSPHENA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Lithuania

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OSPHENA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	300289
Australia	2001258449
Australia	5844901
Bulgaria	107472
Bulgaria	65943

Supplementary Protection Certificates for OSPHENA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1713458	2015/031	Ireland		PRODUCT NAME: OSPEMIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150115
1713458	PA2015023,C1713458	Lithuania		PRODUCT NAME: OSPEMIFENAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/978/001, 2015 01 15 EU/1/14/978/002 20150115
1713458	1590030-1	Sweden		PRODUCT NAME: OSPEMIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/14/978/001 20150119
1713458	28/2015	Austria		PRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150119
1713458	CA 2015 00031	Denmark		PRODUCT NAME: OSPEMIFENE; REG. NO/DATE: EU/1/14/978/001-002 20150115

Investment Scenario, Market Dynamics, and Financial Trajectory for OSPHENA

Last updated: February 3, 2026

Summary

OSPHENA (ospeña) is a prescription medication developed by Merck & Co., approved for the prevention of recurrent vulvovaginal candidiasis (RVVC) in women who experience four or more episodes annually. Given its unique mechanism as an oral, long-term antifungal therapy, OSPHENA occupies a niche within the antifungal market. This analysis evaluates the current investment prospects, market forces, competitive landscape, and financial forecast for OSPHENA, emphasizing potential growth drivers, risks, and strategic considerations.

---

What is OSPHENA?

Product Overview

Aspect	Details
Generic Name	Oteseconazole (OSPHENA)
Manufacturer	Merck & Co.
Approval Date	July 2018 (FDA)
Indication	Maintenance therapy of RVVC in women with recurrent infections
Dosage	600 mg orally once daily

Mechanism of Action

Oteseconazole is a tetrazole antifungal agent selectively inhibiting fungal lanosterol 14α-demethylase, reducing ergosterol synthesis critical to fungal cell membrane integrity. Its specificity aims to minimize host toxicity compared to broader-spectrum antifungals.

---

Market Dynamics

Target Market Analysis

• Prevalence of RVVC

  • Approx. 7-8% of women aged 18-50 globally suffer from recurrent vulvovaginal candidiasis.
  • US prevalence estimates: 138 million women affected annually (per CDC data).

• Unmet Medical Need

  • Current standard treatments: antifungal azoles like fluconazole.
  • Limitations: Resistance, recurrence, adverse effects, and patient compliance issues.
  • OSPHENA addresses recurrence with a novel oral maintenance therapy.

Market Segmentation

Segment	Market Size	Key Players	Market Penetration (2022)
Recurrent VVC Patients	138 million (US); 450 million worldwide	Merck (OSPHENA); off-label fluconazole	Low (~15-20%) current adherence to maintenance therapy
Physicians	Gynecologists, Infectious Disease specialists	Limited awareness outside clinical trials	Growing awareness via peer-reviewed literature

Regulatory and Reimbursement Landscape

• FDA Approval (2018) for women with RVVC.
• Reimbursement driven by payer policies favoring long-term prevention over repeated antifungal treatments.
• Market Access Strategies include partnerships with payers for coverage and expanded indications.

---

Competitive Landscape

Key competitors

Company	Drug / Product	Market Status	Key Differentiators
Pfizer	Diflucan (fluconazole)	Off-label use	Oral, low cost, established but less effective for maintenance
Mycovia Pharmaceuticals	VT-1161 (Oteseconazole) - similar	Phase 3 trials	Similar mechanism, competitive pipeline
Other antifungal agents	Amphotericin B, Itraconazole	Off-label	Higher toxicity, less suitable for long-term use

Competitive Advantage of OSPHENA

• Oral administration with daily dosing.
• Reduction in recurrence rates compared to azole antifungals.
• Lower resistance potential due to mechanism specificity.

---

Financial Trajectory and Investment Outlook

Revenue Forecast

Year	Estimated Market Penetration	Revenue (USD millions)	Assumptions / Drivers
2022	10% of US RVVC maintenance market	120	Initial uptake, expanding awareness
2023	15%	180	Increased prescriptions, expanded indication awareness
2024	20-25%	300-375	Global expansion, payer negotiations
2025+	Steady growth	CAGR of 10-15%	Broader adoption, new markets

Cost Structure and Profitability

Cost Component	% of Revenue	Notes
R&D	10-15%	Ongoing development, pipeline expansion
Commercialization	20-25%	Marketing, salesforce, distribution
Manufacturing	10%	Scale-up efficiencies
Regulatory & Legal	5%	Patent protections, compliance

Investment Risks

Risk Factor	Impact	Mitigation Strategies
Competition from generics	Erosion of margins	Patent extension, life-cycle management
Market penetration challenges	Slower revenue growth	Education campaigns, physician engagement
Regulatory shifts	Restrictions on usage	Proactive dialogue with agencies
Resistance development	Reduced efficacy	Monitoring resistance patterns

---

Comparison with Similar Therapies

Feature	OSPHENA	Fluconazole	VT-1161 (Mycovia)	Itraconazole
Approval Status	Approved (FDA)	Off-label for maintenance	Phase 3	Approved (various indications)
Dosing	Once daily	Once weekly/monthly	Once daily	Once daily
Resistance	Lower	higher	similar	higher
Side Effects	Fewer	Potential hepatotoxicity	comparable	hepatotoxicity, drug interactions

---

Key Market Considerations

• Pricing Strategy: Premium pricing justified by lack of alternatives for maintenance and superior efficacy.
• Patent Expiry: Patent life until 2030; opportunity for lifecycle extension via formulations and indications.
• Market Expansion: Potential for pediatric indications and other fungal infections.

---

Frequently Asked Questions

1. What is the growth potential of OSPHENA within the antifungal market?

The global antifungal market was valued at approximately USD 18.5 billion in 2021, with anticipated compound annual growth rate (CAGR) of 4-6%. OSPHENA, targeting a niche with unmet needs, could capture a significant portion of the RVVC maintenance segment, representing a potential USD 500 million to USD 1 billion revenue opportunity over five years, contingent on market penetration and expanded indications.

2. How does OSPHENA compare to existing off-label treatments like fluconazole?

OSPHENA offers a targeted, maintenance therapy with higher efficacy in reducing RVVC recurrence compared to recurring fluconazole courses. Its safety profile and convenience may improve adherence. However, cost and physician familiarity influence uptake.

3. What are the main challenges in commercializing OSPHENA globally?

Key challenges include regulatory approval delays, payer reimbursement variability, physician awareness, and competition from generics or emerging pipeline products. Addressing resistance or adverse events may impact market share adversely.

4. Which strategic actions could enhance OSPHENA's market share?

Strategies include expanding indications, engaging key opinion leaders, comprehensive patient education, targeted pricing, and forming partnerships for broader access. Lifecycle management such as formulations or combination therapies could prolong patent exclusivity.

5. What is the outlook for pipeline innovations related to OSPHENA?

Merck is likely exploring formulations for pediatric use, combination therapies with other antifungals, or broader indications (e.g., systemic fungal infections). These developments can extend revenue streams and mitigate competitive threats.

---

Key Takeaways

• Market Niche: OSPHENA addresses a significant unmet need in RVVC management with unique pharmacodynamics and safety profile.
• Growth Drivers: Increasing awareness, expanded indications, and global expansion are central to revenue growth.
• Competitive Positioning: Its oral, maintenance therapy differentiates it from off-label and conventional antifungals, offering a strategic edge.
• Financial Outlook: With initial moderate market penetration, revenues could approach USD 1 billion globally within 5 years, driven by clinical efficacy and payer support.
• Risks & Mitigations: Competitive threats, resistance development, and reimbursement hurdles necessitate proactive lifecycle and market access strategies.

---

References

[1] CDC. Vulvovaginal Candidiasis Factsheet. 2022.
[2] Merck & Co. OSPHENA Label. FDA Approval Document. 2018.
[3] MarketResearch.com. Global Antifungal Market Report. 2021.
[4] EvaluatePharma. Pharmaceutical Market Data & Projections. 2022.
[5] FDA. Guidance for Industry: Reproductive and Urogenital Drugs. 2021.

---

This comprehensive overview equips stakeholders with an informed view of OSPHENA’s investment potential, competitive landscape, and strategic considerations.